Filing Analysis
Clene Inc. entered into an underwriting agreement with Canaccord Genuity to sell 1,000,000 shares of common stock at $7.00 per share. The offering is expected to generate approximately $6.4 million in net proceeds to fund the New Drug Application (NDA) filing for lead candidate CNM-Au8 and Phase 3 clinical trials.
Red Flags
- Dilution of existing shareholders through the issuance of 1,000,000 new shares.
- Relatively short lock-up period of only 60 days for insiders.
Key Facts
- Offering of 1,000,000 shares of common stock at a price of $7.00 per share.
- Estimated net proceeds of approximately $6.4 million after underwriting discounts and $140,000 in expenses.
- Underwriting commission set at 6.5% of gross proceeds.
- Proceeds earmarked for CNM-Au8 NDA filing, Phase 3 trials, manufacturing expansion, and potential commercialization.
- 60-day lock-up period for the company, executive officers, and directors.
- Canaccord Genuity LLC is the sole bookrunner; Maxim Group LLC and D. Boral Capital LLC are financial advisors.
Clene Inc. announced it will seek accelerated approval from the FDA for its ALS drug candidate, CNM-Au8, following a successful Type C meeting. The FDA indicated that neurofilament light (NfL) could potentially serve as a surrogate endpoint, allowing for an NDA submission targeted for Q3 2026.
Red Flags
- The FDA's language is non-committal, stating data 'may be' capable of supporting a submission.
- The company must still prove the magnitude of NfL change is 'reasonably likely to predict clinical benefits'.
- The confirmatory Phase 3 trial will not begin until after the NDA is submitted (Q1 2027).
Key Facts
- FDA stated Clene's proposed data 'may be capable of supporting' an NDA submission under the accelerated approval pathway.
- The company intends to submit the NDA in Q3 2026.
- NfL (neurofilament light) is being used as a surrogate endpoint to predict clinical benefit.
- A Phase 3 confirmatory study is planned to commence in Q1 2027.
- Submission data includes Phase 2 HEALEY ALS Platform Trial, RESCUE-ALS Trial, and NIH-sponsored Expanded Access Protocol data.
- CNM-Au8 has previously received Orphan Drug Designation for ALS.
Clene Inc. entered into an $8.0 million subaward agreement with New York University for the third year of a four-year, $45.1 million NIH grant. The funding supports the company's Expanded Access Program for its ALS treatment candidate, CNM-Au8.
Key Facts
- Agreement signed March 13, 2026, with New York University (NYU) as the prime awardee.
- The subaward provides up to $8.0 million for the period from September 1, 2025, to August 31, 2026.
- This is the third year of a $45.1 million NIH grant originally announced in October 2023.
- The grant supports the treatment of amyotrophic lateral sclerosis (ALS) under the Accelerating Access to Critical Therapies for ALS Act.
- Funding is disbursed via monthly reimbursement invoices.
- The agreement includes a 30-day termination clause for either party.
Clene Inc. reported its full year 2025 operating and financial results on March 12, 2026. The filing serves as a formal disclosure of the company's year-end performance via an attached press release.
Key Facts
- The filing was made on March 12, 2026, covering the fiscal year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was included as Exhibit 99.1.
- The company is listed on the Nasdaq Capital Market under the ticker CLNN.
Clene Inc. issued a press release and a letter to stockholders on February 24, 2026, detailing upcoming 2026 catalysts for its lead drug candidate, CNM-Au8. The filing serves as a routine investor update regarding the company's clinical and operational outlook.
Key Facts
- Issued press release on February 24, 2026.
- Highlighted upcoming 2026 catalysts for lead candidate CNM-Au8.
- The disclosure was made under Item 8.01 (Other Events).
- Incorporated Exhibit 99.1 (Press Release) by reference.